Chembio Diagnostics, Inc. (CEMI) - NASDAQ
  • Fri, Feb. 19, 9:24 AM
    • Chembio (NASDAQ:CEMI) is up 11% premarket on increased volume in response to its announcement that it has been awarded a $550K catalyst grant from the Paul G. Allen Family Foundation to develop a point-of-care (POC) diagnostic test for Zika virus and related febrile illnesses.
    • The company intends to employ its Dual Path Platform technology to develop a stand-alone POC assay to simultaneously detect the Zika, Dengue and Chikungunya viruses. It also plans to add Zika to its POC DPP Fever Panel that is currently under development through a separate grant under the Paul G. Allen Ebola Program.
    | Fri, Feb. 19, 9:24 AM
  • Fri, Feb. 19, 9:15 AM
    | Fri, Feb. 19, 9:15 AM
  • Oct. 30, 2014, 9:18 AM
    | Oct. 30, 2014, 9:18 AM | 1 Comment
  • Oct. 27, 2014, 12:49 PM
    | Oct. 27, 2014, 12:49 PM
  • Oct. 27, 2014, 9:13 AM
    | Oct. 27, 2014, 9:13 AM | 1 Comment
  • Oct. 13, 2014, 9:15 AM
    | Oct. 13, 2014, 9:15 AM
  • Sep. 5, 2013, 10:55 AM
    • Chembio Diagnostics (CEMI +2.8%) says its CEO and President Lawrence A. Siebert will retire when his contract expires May 11, 2014.
    • The company has begun a search for a new CEO.
    | Sep. 5, 2013, 10:55 AM
  • Aug. 5, 2013, 12:45 PM
    | Aug. 5, 2013, 12:45 PM
  • Jun. 18, 2013, 9:20 AM

    Chembio Diagnostics (CEMI) jumps 3.4% premarket after saying its FDA-approved Clearview COMPLETE HIV 1/2 assay has received CE Mark approval in Europe. The product will be marketed in the EU under the name SURE CHECK, and CEMI says it expects sales as soon as Q1 2014. (PR)

    | Jun. 18, 2013, 9:20 AM
  • May 23, 2013, 10:59 AM

    Chembio Diagnostics (CEMI +0.2%) bucks a weak tape after saying it won a $750K cooperative research agreement with a US government agency to develop rapid point-of-carediagnostic tests for five infectious diseases associated with febrile illness and to multiplex them into one assay. The eight-month project also hopes to optimize the test for use with a mobile reader that incorporates cell phone technology to enable the results to be recorded, transmitted and monitored remotely via a cloud system, in real-time.

    | May 23, 2013, 10:59 AM | 1 Comment
  • May 21, 2013, 11:03 AM

    Chembio Diagnostics (CEMI +4.1%) gains after entering into an international assembly and distribution agreement with Labtest Diagnostica SA, a leading diagnostics manufacturer and marketing organization in Brazil, for products based upon its patented Dual Path Platform in Brazil and potentially other markets in the region as well. Both companies plan to immediately begin product registration for an initial group of infectious disease products with sales expected to commence by early 2014.

    | May 21, 2013, 11:03 AM
  • May 16, 2013, 3:04 PM

    Chembio Diagnostics (CEMI -1.3%) says it's entered into a six-month follow-on, milestone-based development agreement with a private contracting organization to implement and provide technical oversight relating to pandemic preparedness on behalf of the US Centers for Disease Control and Prevention, for a rapid, POC influenza immunity test utilizing CEMI's patented Dual Path Platform technology.

    | May 16, 2013, 3:04 PM
  • Apr. 18, 2013, 3:08 PM

    Chembio Diagnostics (CEMI +5.4%) trades up after saying it's commenced Clinical Laboratory Improvement Amendments waiver studies for its DPP HIV 1/2 Assay. The studies are required by the FDA to establish the quality standards for laboratory testing, which ensures the accuracy, reliability and timeliness of patient tests results regardless of where the tests are performed.

    | Apr. 18, 2013, 3:08 PM
  • Mar. 28, 2013, 10:45 AM

    Chembio Diagnostics (CEMI -3.8%) slips after pricing a public offering of 1.2M shares at $5, a 2.9% discount to Wednesday's close. Net proceeds on the sale come to around $5.5M, for which the maker of diagnostic testing equipment maker plans to use the funds for business expansion and working capital. Prior to the offering, it's current float stood at about 8.09M shares. Craig-Hallum is the sole book-running manager.

    | Mar. 28, 2013, 10:45 AM
  • Mar. 7, 2013, 5:06 PM
    Chembio Diagnostics (CEMI): Q4 EPS of $0.06 beats by $0.01. Revenue of $7.87M (+27% Y/Y) beats by $0.6M. Shares +3.8% AH. (PR)
    | Mar. 7, 2013, 5:06 PM
  • Jan. 29, 2013, 2:32 PM

    Shares of Chembio Diagnostics (CEMI +4.2%) moves higher after the USDA approves its CervidTB STAT-PAK and DPP VetTB test kits as primary and secondary tests for bovine tuberculosis by the USDA Animal and Plant Health Inspection Service. The approval was made in order to provide the farmed deer industry with more options for meeting testing requirements for captive elk and deer.

    | Jan. 29, 2013, 2:32 PM
Company Description
Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. Its main products presently commercially available are four rapid tests for the detection of HIV antibodies. It sells its products under its STAT PAK, SURE... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: United States